China’s new drug law may open door for Indian generic medicines: Report

Source: Financial Express, Aug 28, 2019

China’s revised drug law, which removes drugs that are legal in foreign countries but not approved in China from the category of fake medicines, may allow entry of Indian generic medicines in the country, media reports said on Tuesday. China’s top legislature, the Standing Committee of National People’s Congress, passed the revised law on Monday to enhance management and supervision of the pharmaceutical market following numerous fake drugs and vaccine cases that had triggered a call for stronger measures to ensure drug safety.

India has been demanding that China open its pharmaceutical market to Indian drugs as part of the efforts to lower the USD 57 billion trade deficit in about USD 95.5 billion total trade last year. No major Indian pharma company managed to establish itself in China in view of the rigid regulations and the costs involved. Legal foreign drugs, including generic drugs from India, will not be treated as fake medicine in China based on a revised drug administration law that will take effect on December 1, state-run Global Times reported. Read the rest of this entry »

District-wise data on pharma exports soon

Source: The Hindu Business Line, Aug 20, 2019

Hyderabad: The Pharmaceutical Export Promotion Council (Pharmexcil) is building a database to capture district-wise pharmaceutical exports.

“We have been asked by the Department of Commerce to compile district-wise pharmaceutical exports data,’’ Uday Bhaskar, Diector General, Pharmexcil, told BusinessLine.

As part of the initiative, details of exports of bulk drugs, formulations, Ayush, herbals and surgicals are being collected.

“To start with, we will compile data for the last three financial years,” he said. Read the rest of this entry »

Pakistan imported medicines worth Rs 136 crore from India in 2019

Source: The Economic Times, Jul 15, 2019

Pakistan imported medicines and vaccines worth (Pakistani) Rs 136,99,87,000 from India in 2019, its Health Ministry has said.

Express News reported that the imported medicines included life-saving drugs, tablets, syrups and vaccines.

According to figures announced by the Pakistan Health Ministry in Senate on Friday, the country imported drugs and vaccines worth (Pakistani) Rs 15,43,17,000 in January; Rs 22,32,47,000 in February; Rs 19,37,37,000 in March; Rs 11,10,42,000 in April; Rs 18,96,47,000 in May and Rs 4,89,12,000 from India. Read the rest of this entry »

Indian pharma industry to grow at 11-13 per cent in FY20

Source: IBEF.org, Jul 08, 2019

As healthy demand from the domestic market, given increasing spend on healthcare along with improving access, the growth of Indian pharmaceutical industry is likely to grow at 11-13 per cent in FY20.

This along with moderation in pricing pressure for US market, new dispatches and market share gains for existing products and union advantages will drive growth in FY20
And, the growth would be compelled by administrative interventions, such as, value controls, mandatory genericisation and United States Food and Drug Administration (USFDA) oversight for assembling insufficiencies”.

According to an Icra report, covering a sample of 21 firms in the industry, the growth during FY2019 stood at around 12 per cent. Read the rest of this entry »

Pharma sales growth hit 19-month low in May as product launches slowed down

Source: Business Standard, Jun 15, 2019

Mumbai: The domestic pharmaceuticals market clocked 7 per cent year-on-year (YoY) growth in May, the lowest since October 2017, when it registered a growth of 4.9 per cent.

For the first time, all chronic therapy drugs grew only in single digits during May.

According to analysts, a slew of factors were responsible for the slowdown — a weak season resulting in lower offtake (mainly acute therapy medicines), slump in product launches in the chronic segment pulling down the growth of therapy drugs, apart from the impact of price regulation in the overall market.

“Many chronic therapy medicines for hypertension, diabetes and cardiac ailments have come under price control. The price growth in these brands has thus slowed down. Companies cannot stop production of medicines that are under price control but can reduce production by 25 per cent every year. Several companies have done that eventually slowing the volume growth,” said a senior official of a drug firm that has a sizeable domestic portfolio. Read the rest of this entry »

Indian pharma industry likely to grow by 11% to $41.9 bn in FY20: Report

Source: Business Standard, Jun 13, 2019

Bhubaneswar: Helped by the growth in domestic and export markets, India’s pharma industry is set to rise by 9-11 per cent over the previous fiscal and it is likely to touch $41.9 billion in FY20.

While on the domestic front, the industry is expected to grow at around 12 per cent and reach $20.4-$20.8 billion during FY20, exports are likely to touch $21.1 billion in this fiscal with a growth rate of 8 to 10 per cent, according to a study by Care Ratings.

“Moreover, the need for affordable healthcare in pharmemerging and developed nations are likely to support exports of branded generics to these countries. Also, rising per capita incomes in pharmemerging nations will contribute to the rise in branded generics exports from India”, Manufacturing & Service Industries: Review FY19 & Outlook FY20 report said.

In addition to this, patent expiry or loss of brand exclusivity is also expected to result in higher exports of generic drugs. Read the rest of this entry »

Industry blames policies, USFDA probes for 73% drop in pharma FDI

Source: Business Standard, Jun 09, 2019

Chennai: Foreign Direct Investment (FDI) equity inflows into the country’s drugs and pharma industry dropped by 73 per cent to $266 million (around Rs 1,842 crore) between April 2018 and March 2019, from $1.010 billion (around Rs 6,502 crore), during the same period a year ago. Industry representatives have attributed policies and USFDA investigations into the practices of certain Indian Pharma companies among the key reasons for the decline.

While pharma companies have not responded to queries related to the decline, experts believe the sector may not attract investments till attractive and investor-friendly policies are introduced. Read the rest of this entry »